

Haematologica
HAEMATOL/2020/260117
Version 3

Complement C5 inhibition in patients with COVID-19 - a promising target?

Regis Peffault de Latour, Anne Bergeron, Etienne Lengline, Thibault Dupont, Armance Marchal, Lionel Galicier, Nathalie de Castro, Louise Bondeelle, Michael Darmon, Clairelyne Dupin, Guillaume Dumas, Pierre Leguen, Isabelle Madelaine, Sylvie Chevret, Jean-Michel Molina, Elie Azoulay, and Veronique Fremeaux-Bacchi
(Collaborative Groups: CORE GROUP)

Disclosures: R. Peffault de Latour received research grants or consulting fees from Alexion, Novartis and Pfizer. V. Fremeaux-Bacchi received consultancy and/or lecture fees and/or travel support from Alexion Pharmaceuticals, Inc., Apellis, and Roche.

Contributions: Conception and design: RPL, AB, SC, EA and VFB Provision of study materials and patients: AB, EL, TD, NC, LB, MD, CD, GD, PL, JMM and EA Data collection and assembly: RPL, AB, EA and VFB Data analysis and interpretation: RPL, AB, EA and VFB Manuscript writing: RPL, AB, EA and VFB Final approval of manuscript: RPL, AB, EL, TD, AM, LG, NC, LB, MD, CD, GD, PL, IM, SC, JMM, EA and VFB The Saint Louis CORE group is a collaborating group of clinicians, radiologists, biologists, pharmacists and clinical research assistants of Saint Louis Hospital. They all have participated to the care of patients with COVID19 and/or to research into COVID19 in Saint Louis Hospital, Paris, during the SARS-COV2 epidemic. They decided to share their data to ease local research into COVID19. All the manuscript written on behalf of the Saint Louis CORE group has been, preliminary to submission, sent to all members for critical rereading and consent for publication.